Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
June 07 2021 - 5:19PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today joined state and local officials, fellow
tenants, and community partners, in a groundbreaking ceremony for
101 College Street, a new 525,000-square-foot-building to be
constructed as part of New Haven’s Downtown Crossing revitalization
project. Arvinas will lease three of the 10 floors at 101 College
and this space will serve as the Company’s headquarters beginning
in 2024.
“Today’s groundbreaking ceremony marks an exciting milestone for
Arvinas and will allow us to continue our rapid growth in the years
ahead,” said John Houston, Ph.D., President and Chief Executive
Officer at Arvinas. “We are thrilled to contribute to the growing
biopharmaceutical hub and development of the overall
community.”
Construction of 101 College is scheduled to begin in the first
half of 2021, and the Arvinas space is estimated to be complete and
open for occupancy in 2024. Arvinas will occupy approximately
160,000-square-feet of lab and office accommodations. Arvinas will
remain at its current location in Science Park until 101 College is
available for occupancy.
Construction of 101 College in the Downtown Crossing section of
New Haven is an important step in the revitalization of the City's
downtown neighborhoods. When complete, Downtown Crossing will
create a connected, walkable community in New Haven’s life sciences
district, ease traffic, and bolster Connecticut’s
economy. Notably, the project will help connect Yale’s medical
and central campuses with world-class life science companies and
hundreds of skilled employees. Downtown Crossing is funded by the
U.S. Department of Transportation’s TIGER II grant, the City of New
Haven, and the State of Connecticut. Winstanley Enterprises, LLC.,
is the developer on this multi-tenant project.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties,. All statements, other than statements of
historical facts, contained in this press release, including
statements regarding our strategy, future operations, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
including important factors discussed in the “Risk Factors”
sections contained in our quarterly and annual reports on file with
the Securities and Exchange Commission. The forward-looking
statements contained in this press release reflect our current
views with respect to future events, and we assume no obligation to
update any forward-looking statements except as required by
applicable law. These forward-looking statements should not be
relied upon as representing our views as of any date subsequent to
the date of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/36f43554-3353-4335-8726-96ef1e345712
Contacts for
ArvinasInvestorsWill O’Connor, Stern
Investor Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024